Keith Meister Acquires 140,026 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) Director Keith Meister acquired 140,026 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was purchased at an average price of $81.19 per share, with a total value of $11,368,710.94. Following the transaction, the director owned 3,228,150 shares in the company, valued at $262,093,498.50. This represents a 4.53% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

GeneDx Trading Up 7.5%

NASDAQ WGS opened at $88.11 on Friday. GeneDx Holdings Corp. has a one year low of $55.17 and a one year high of $170.87. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.46 and a quick ratio of 2.34. The firm has a market cap of $2.58 billion, a P/E ratio of -117.48 and a beta of 2.03. The stock’s 50-day moving average is $100.80 and its 200-day moving average is $122.16.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.03. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The business had revenue of $120.99 million during the quarter, compared to analyst estimates of $120.80 million. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Wall Street Zen lowered shares of GeneDx from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. BTIG Research lowered their target price on GeneDx from $200.00 to $170.00 and set a “buy” rating for the company in a report on Tuesday, February 24th. Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Finally, Canaccord Genuity Group boosted their price target on GeneDx from $160.00 to $170.00 and gave the company a “buy” rating in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, GeneDx currently has an average rating of “Moderate Buy” and an average target price of $150.71.

Institutional Trading of GeneDx

Several hedge funds and other institutional investors have recently modified their holdings of WGS. ARK Investment Management LLC acquired a new position in shares of GeneDx in the third quarter valued at approximately $48,157,000. Rhumbline Advisers boosted its stake in GeneDx by 42.7% in the 2nd quarter. Rhumbline Advisers now owns 27,610 shares of the company’s stock valued at $2,549,000 after purchasing an additional 8,258 shares during the period. Principal Financial Group Inc. grew its holdings in GeneDx by 340.4% in the 3rd quarter. Principal Financial Group Inc. now owns 59,624 shares of the company’s stock valued at $6,424,000 after buying an additional 46,085 shares in the last quarter. Impax Asset Management Group plc bought a new position in GeneDx during the 3rd quarter worth $5,387,000. Finally, Legal & General Group Plc lifted its holdings in shares of GeneDx by 55.9% during the second quarter. Legal & General Group Plc now owns 22,271 shares of the company’s stock worth $2,056,000 after buying an additional 7,987 shares in the last quarter. Institutional investors own 61.72% of the company’s stock.

Key Headlines Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Large affiliated/institutional buy: Corvex Management reported a purchase of GeneDx shares worth roughly $13.4 million, a strong signal of institutional confidence that can support the stock. Corvex management buys GeneDx (WGS) shares worth $13.4 million
• Positive Sentiment: Director buying: Director Keith A. Meister made two recent purchases (140,026 shares on Mar 5 at ~$81.19 and 29,495 shares on Mar 3 at ~$70.89), increasing his stake to over 3.2M shares — a large insider accumulation that typically signals confidence and can drive demand. SEC ownership filing — Keith A. Meister purchases
• Positive Sentiment: Recent earnings beat: GeneDx topped consensus on its most recent quarterly EPS and delivered revenue roughly in line with estimates, supporting a bullish narrative around recurring revenue and margin progress (analyst consensus remains a Moderate Buy with elevated price targets).
• Neutral Sentiment: Short-interest reading shows 0 reported short interest as of Mar 5, which appears to be a data anomaly and offers little actionable signal on immediate directional pressure.
• Negative Sentiment: CEO sale: CEO Katherine Stueland sold 25,459 shares on Mar 4 (~$2.0M) and cut her direct stake materially. Significant insider sales can worry some investors about insiders taking liquidity. SEC Form 4 — CEO sale
• Negative Sentiment: CFO sale: CFO Kevin Feeley sold 6,187 shares on Mar 4 (~$486k), trimming his position by roughly 25%; this adds to mixed insider signals even though the size is smaller than the institutional buys. SEC Form 4 — CFO sale

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.